Bioasis Announces Closing of Previously Disclosed Private Placement

Bioasis Technologies (TSX.V:BTI; OTCQB:BIOAF) (“Bioasis” or the “Company”), a biopharmaceutical company developing its xB3 TM proprietary platform technology for the delivery of therapeutics across the blood-brain barrier...

Bioasis Announces Positive Results from a Microdialysis Study Showing Lead Investigational Candidate xB3 ™-001...

Tailwinds' Take: This is excellent progress. If it translates into human data, a decent probability, it could be huge. Once they get properly funded...

Bioasis and BioAgilytix Announce Strategic Collaboration to Advance xB3 TM-001, Bioasis’ Lead Investigational Candidate...

RICHMOND, British Columbia & GUILFORD, Conn. & DURHAM, N.C.–(Business Wire)– Bioasis Technologies, Inc . (TSX.V:BTI; OTCQB:BIOAF), a biopharmaceutical company developing its xB3 TM proprietary platform technology for the...

Bioasis Further Strengthens Scientific Advisory Board with Addition of Dr. Mario Saltarelli, Dr. Jack...

Tailwinds' Take: Scientists of this caliber don't join SABs unless there's something exciting going on. We eagerly anticipate the release of Non-Human Primate data...

Micros Rally Broadly…May in Review

The Big Picture Sometimes you get a little out of touch living in California (duh!). For one thing, the lack of a real winter can...

Bioasis Announces Publication of Independent Validation of the Company’s xB3 ™ Platform Technology

Tailwinds' Take: Great news! xB3 is poised to be a game-changing platform for treatment of CNS diseases. Still early stage, but the opportunity deserves...

Bioasis and WuXi Biologics Announce Initial Strategic Collaboration for the Development and Manufacturing of...

Tailwinds' Take: having a manufacturing partner is a key step towards clinical development of their drug candidates. With their recent financing, which we believe...

With Earnings Season Over, Which Stocks Surprised Us?

Quarterly earnings season is the four times each year in which companies give investors an inside look as to what's going on. They not...

Bioasis Announces Closing of First Tranche of Previously Disclosed Private Placement

Tailwinds' Take: the closing of this private placement is a key catalyst for Bioasis shares. We have been adding in the Tailwinds portfolios and...

Bioasis: Prepping for Financing, but Buying Opportunity Awaits

When I removed Bioasis from the Tailwinds Select Portfolio, it was with great reluctance. This is a Company that I believe has groundbreaking, lifesaving,...

Bioasis Announces Key Strategic Appointment to its Senior Leadership Team with Addition of Caroline...

VANCOUVER, British Columbia & GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc . (OTCQB:BIOAF; TSX.V:BTI), a biopharmaceutical company with a proprietary blood-brain barrier platform delivery technology focused on development...

Bioasis Appoints Deborah Rathjen, B.Sc. (Hons), Ph.D., MAICD, FTSE as Chair of the Board...

VANCOUVER, British Columbia & GUILFORD, Conn.–(Business Wire)– Bioasis TECHNOLOGIES, INC . (TSX.V:BTI; OTCQB:BIOAF), a biopharmaceutical company with a proprietary blood-brain barrier platform technology focused on development of...

biOasis Technologies Inc. Appoints Christopher P. Lowe as CFO

Tailwinds' Take: new CEO Mark Day continues to build out a professional team as they look to take biOasis to the next level. We...

biOasis Announces Voting Results for 2017 Annual Meeting

Vancouver, BC, BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) today announced the voting results from its Annual General Meeting held on Sept. 21, 2017 in Vancouver,...

Bioasis Announces Rob Hutchison, Founder, to Retire as Chairman & Board Member

Tailwinds' Take: it looks like Dr. Day is being given the keys to the house as the founder steps aside. The new CEO's background...